MedTrace Logo

The Combination of ATRA and Danazol as Second-line Treatment in Adult Immune Thrombocytopenia

NCT01667263 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2017-09-07

No results posted yet for this study

Summary

Randomized, open-label, multicentre study to compare the efficacy and safety of ATRA plus danazol with danazol monotherapy in patients with corticosteroid-resistant/relapsed ITP.

Conditions

  • Autoimmune Thrombocytopenia

Interventions

DRUG

All-trans retinoic acid

DRUG

Danazol

Sponsors & Collaborators

  • Beijing Municipal Science & Technology Commission

    collaborator OTHER

  • Beijing Hospital

    collaborator OTHER_GOV

  • Qilu Hospital of Shandong University

    collaborator OTHER

  • Navy General Hospital, Beijing

    collaborator OTHER

  • Beijing Tongren Hospital

    collaborator OTHER

  • Peking University People's Hospital

    lead OTHER

Principal Investigators

  • Xiao-Hui Zhang, Professor · Peking University People's Hospital, Peking University Insititute of Hematology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-01
Primary Completion
2016-07-01
Completion
2017-02-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01667263 on ClinicalTrials.gov